Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Claimed Company
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions read more
Karyopharm Therapeutics Executive Salaries
Key Executives
Name
Title
Salary
Total Comp Total Compensation includes both short-term and long-term benefits, option grants, salary, bonuses, company perks, etc. that can be used to determine financial benefits. An executive may or may not realize all of the Total Co mpensation during their tenure at the Company. Values of the benefits may change over time.
Co-Founder, Co-Chairman of Scientific Advisory Board, President & Chief Scientific Officer
$415k
$1.35M
The average Karyopharm Therapeutics executive compensation is $235,802 a year. Karyopharm Therapeutics' highest paid executives include: Sharon Shacham Ph.D., M.B.A. $1,350,783.
The median estimated compensation for executives at Karyopharm Therapeutics including base salary and bonus is $237,449, or $114 per hour.
Last updated months ago.
$105k
$170k
$237k
$345k
$450k
$563k
$576k
$235,802*
Average Compensation
$237,449*
Median Compensation
* Estimated salaries Estimated salaries are based on data provided anonymously by employees and/or estimated by other statistical methods.
×